[Effect of cinobufagin on nuclear factor-kappaB pathway in HepG2 cells].
OBJECTIVE
To investigate the effect of cinobufagin on nuclear factor-kappaB (NF-kappaB) pathway of liver cancer cell line HepG2.


METHODS
Dual-luciferase cis-reporting system was used to detect the relative value of pNF-kappaB-TA-luc upon tumor necrosis factor-alpha (TNF-alpha) stimulation of NF-kappaB pathway. Western blotting was used to detect the protein level of NF-kappaB p65, and RT-PCR was used to detect the gene transcription level of intercellular adhesion molecule-1 (ICAM-1), a target downstream gene of NF-kappaB.


RESULTS
At the concentration of 0.25 and 0.5 microg/ml, cinobufagin significantly lowered the relative value of luciferase (P<0.05). The results of Western blotting showed that cinobufagin significantly suppressed the protein expression of NF-kappaB p65. The transcription level of ICAM-1 was reduced by different doses of cinobufagin.


CONCLUSIONS
The anti-cancer effect of cinobufagin may be related to its activity in inhibiting the activation of NF-kappaB pathway.
Dong
Yun-qiao
YQ
Institute of Genetic Engineering, Southern Medical University, Guangzhou 510515, China. dongyunqiao@126.com
Ma
Wen-li
WL
Gu
Jin-bao
JB
Zheng
Wen-ling
WL
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002018:Bufanolides / Q000494:pharmacology*; D056945:Hep G2 Cells; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics / Q000378:metabolism; D008419:Materia Medica / Q000494:pharmacology; D016328:NF-kappa B / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects*; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D002018:Bufanolides; D008419:Materia Medica; D016328:NF-kappa B; D051996:Transcription Factor RelA; D018799:Intercellular Adhesion Molecule-1; C002471:cinobufagin